Update： 2017-06-23 21:15:16
Extracellular vesicles (EVs) are lipid membrane-enclosed vesicles released by cells and present in bodily fluids. They are heterogeneous in composition and size, ranging from approximately 50 to 1000 nm, with the vast majority < 200 nm in size. EVs play important roles in a plethora of (patho)physiological processes and are increasingly recognized as biomarkers for disease. In addition, engineered EV and EV-inspired liposomes hold great potential as drug delivery systems.
Dr. Jennifer Jones and members of her group in the National Cancer Institute, National Institutes of Health, Bethesda, MD, United States have been working on a research program with one of the major aims to delineate the molecular profiles of the contents of EV subsets. All types of EVs are composed of various protein and lipid species reflecting the status and the cell of origin, and contain various cargo (DNA, RNA, protein). Detection and molecular profiling of EVs is technically challenging and often requires extensive sample purification and labeling.
Given the difficulties with EVs profiling, Dr. Jennifer Jones acquired a NanoFCM instrument in January to characterize various parameters of the EVs. She and her team assayed the plasma EV expression of more than 300 epitopes, using PE-conjugated monoclonal antibodies against human cell surface markers and isotype controls, they were excited to know that NanoFCM enables detection of low- to intermediate-levels of EV surface markers.
Dr. Jennifer Jones gave a talk entitled “High sensitivity, quantitative epitope analysis of plasma EVs by flow cytometry” in ISEV 2017, and “Molecular profiling limits tumor-derived extracellular vesicles” in CYTO 2017, where she gave a detailed presentation of the results obtained with our nanoFCM instrument.
“The nanoFCM demonstrated 10-100-fold higher sensitivity, and a commensurate ability to detect epitope-positive EVs that are too dim to be detected with most available flow- or image- cytometers”, said Dr. Jennifer Jones.